LongeVC invests in early-stage biotechnology and longevity companies that address the biological mechanisms of aging and age-related diseases, backing founders pioneering breakthrough therapeutics, diagnostics, and platform technologies. It prioritizes science-driven ventures with strong translational potential from pre-clinical to clinical impact, including AI-enabled drug discovery and personalized medicine. The firm leverages a deep network of scientific advisors to source proprietary deal flow and applies rigorous domain expertise in evaluation, aiming to de-risk early biotech investments and accelerate meaningful advances in healthspan. Through capital, ecosystem support, and strategic connections, LongeVC seeks to catalyze innovations that can materially extend healthy human life and deliver outsized returns for investors.